Key result
Pre-event antiplatelet therapy significantly decreased the incidence of large artery atherosclerosis stroke (OR 0.88; 95% CI 0.79-0.99; P=0.026) but increased cardioembolic stroke incidence.
Why the study?
Does pre-event antiplatelet therapy alter the incidence of specific ischaemic stroke subtypes in patients?
Meta-Analysis (n=5,739)
Does pre-event antiplatelet therapy alter the incidence of specific ischaemic stroke subtypes in patients?
Odds Ratio: 0.88 (95% CI 0.79–0.99)
p-value: p=0.026
Antiplatelet therapy preferentially reduces the incidence of large artery atherosclerosis stroke compared with cardioembolic and small vessel occlusion subtypes.
No takes yet. Share an insight, caveat, or question.
Pre-event antiplatelet therapy warrants caution in cardioembolic-prone patients; extends evidence for etiology-specific stroke prevention effects.
Rajkumar et al. (2015) conducted a meta-analysis in Ischaemic stroke (n=5,739). Antiplatelet therapy vs. No antiplatelet therapy was evaluated on Incidence of large artery atherosclerosis (LAA) stroke (OR 0.88, 95% CI 0.79-0.99, p=0.026). Pre-event antiplatelet therapy significantly decreased the incidence of large artery atherosclerosis stroke (OR 0.88; 95% CI 0.79-0.99; P=0.026) but increased cardioembolic stroke incidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: